Search for 'an,phr: 1793'

Phase II clinical trial of PM00104 (Zalypsis(®)) in urothelial carcinoma patients progressing after first-line platinum-based regimen.

By Castellano, Daniel | Ghanem Cañete, Ismael. Cancer chemotherapy and pharmacology, 2014 . 73(4):857-67. , Formato Vancouver: Castellano DE, Bellmunt J, Maroto JP, Font Pous A, Morales Barrera R, Ghanem I et al. Phase II clinical trial of PM00104 (Zalypsis(®)) in urothelial carcinoma patients progressing after first-line platinum-based regimen. Cancer Chemother Pharmacol. 2014 Apr;73(4):857-67.

Place Hold on Phase II clinical trial of PM00104 (Zalypsis(®)) in urothelial carcinoma patients progressing after first-line platinum-based regimen.

Safety and efficacy of metronomic non-pegylated liposomal encapsulated doxorubicin in heavily pretreated advanced breast cancer patients.

By Ciruelos Gil, Eva María | Cortés-Funes Castro, Hernán | Dorta Suárez, Myriam | Ghanem Cañete, Ismael | Manneh Kopp, Ray | Manso Sánchez, Luis | Mendiola Fernández, César | Sepúlveda Sánchez, Juan Manuel | Valdiviezo N, | Vega Alonso, Estela. Clinical & translational oncology: official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2013 . 15(6):467-71. , Formato Vancouver: Manso L, Valdiviezo N, Sepúlveda J, Ciruelos E, Mendiola C, Ghanem I, et al. Safety and efficacy of metronomic non-pegylated liposomal encapsulated doxorubicin in heavily pretreated advanced breast cancer patients. Clin Transl Oncol. 2013 Jun;15(6):467-71.

Place Hold on Safety and efficacy of metronomic non-pegylated liposomal encapsulated doxorubicin in heavily pretreated advanced breast cancer patients.

RC0639: phase II study of paclitaxel, trastuzumab, and lapatinib as adjuvant therapy for early stage HER2-positive breast cancer.

By Ghanem Cañete, Ismael. Breast cancer research and treatment, 2013 . 138(2):427-35. , Formato Vancouver: Moreno-Aspitia A, Dueck AC, Ghanem-Cañete I, Patel T, Dakhil S, Johnson D et al. RC0639: phase II study of paclitaxel, trastuzumab, and lapatinib as adjuvant therapy for early stage HER2-positive breast cancer. Breast Cancer Res Treat. 2013 Apr;138(2):427-35.

Place Hold on RC0639: phase II study of paclitaxel, trastuzumab, and lapatinib as adjuvant therapy for early stage HER2-positive breast cancer.

Role of inhibitors of mammalian target of rapamycin in the treatment of luminal breast cancer.

By Ciruelos Gil, Eva María | Cortés-Funes Castro, Hernán | Ghanem Cañete, Ismael | Manso Sánchez, Luis. Anti-Cancer Drugs, 2013 . 24(8):769-80. , Formato Vancouver: Ciruelos E, Cortés-Funes H, Ghanem I, Manso L, Arteaga C. Role of inhibitors of mammalian target of rapamycin in the treatment of luminal breast cancer. Anticancer Drugs. 2013 Sep;24(8):769-80.

Place Hold on Role of inhibitors of mammalian target of rapamycin in the treatment of luminal breast cancer.

Safety and efficacy of moderate-dose capecitabine as first-line therapy in metastatic breast cancer

By Cortés-Funes Castro, Hernán | Ghanem Cañete, Ismael. Expert Review of Anticancer Therapy, 2011 . 11(2):165-168. , Formato Vancouver: Cortes-Funes H, Ghanem I. Safety and efficacy of moderate-dose capecitabine as first-line therapy in metastatic breast cancer. Expert Rev Anticancer Ther. 2011 Feb;11(2):165-8.

Place Hold on Safety and efficacy of moderate-dose capecitabine as first-line therapy in metastatic breast cancer